RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbre ...
Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for ...
Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...
The Chosun Ilbo on MSN
Cosmo's topical hair loss breakthrough after 30 years
Italian pharmaceutical company Cosmo Pharmaceuticals recently announced that its newly developed male-pattern hair loss ...
3d
FDA panel recommends testosterone therapy be more accessible to men, knocks ‘outdated’ restrictions
The narrow FDA labeling makes it so that only a minority of men who could benefit from treatment are considered ‘on-label’ ...
Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December ...
Confused about which painkiller to use? Pharmacist Meritxell Martí provides a definitive guide on how to take ibuprofen and ...
Privo Technologies, Inc., today announced that the first patient has been dosed in its first-in-human clinical trial evaluating PRV131 ...
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonaltopical ...
Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics (R) , today announced the close of its $25 million, twice-oversubscribed Series B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback